Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

AbbVie (ABBV)

NYSE: ABBV · Pharmaceuticals · North Chicago, IL

Our rating: Neutral

Call changed from Positive to Neutral at $294.83, moderate conviction, November 4, 2026.

Breaks if: The Neutral call turns Positive if revenue growth accelerates to 12% or above in two consecutive reported quarters within the next 12 months while free cash flow holds at or above $17 billion on a trailing annual basis. It turns Cautious if revenue growth falls to below 4% year over year for two consecutive reported quarters, or if trailing twelve-month free cash flow drops below $13 billion in any reported period.

Key figures

Market value$505.9B
Revenue, last 12 months$66.0B
Net income, last 12 months$10.3B
Free cash flow, last 12 months$18.9B
Price to earnings48.9×
Free cash flow yield3.7%
Dividend yield2.4%
Operating margin32.2%
Return on equityn/a
Beta to the S&P 5000.24
Volatility, annualized26.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$17.4B10.3%$2.37$7.3B
June 30, 2026$17.0B10.2%$2.03$3.1B
March 31, 2026$15.0B12.4%$0.39$3.6B
December 31, 2025$16.6B10.0%$1.02$4.9B
September 30, 2025$15.8B9.1%$0.10$6.6B
June 30, 2025$15.4B6.6%$0.52$4.9B
March 31, 2025$13.3B8.4%$0.72$1.4B
December 31, 2024$15.1B5.6%$-0.02$6.8B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.